Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib

被引：14
|
作者：
Ikezoe, Takayuki [1 ]
Togitani, Kazuto [1 ]
Tasaka, Taizo [2 ]
Nishioka, Chie [1 ]
Yokoyama, Akihito [1 ]
机构：
[1] Kochi Univ, Dept Hematol & Resp Med, Nanko Ku, Kochi 7838505, Japan
[2] Kawasaki Med Sch, Dept Lab Med, Okayama, Japan
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 08期
关键词：
TYROSINE KINASE INHIBITOR; LEUKEMIA;
D O I：
10.1016/j.leukres.2010.02.024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E200 / E201
页数：2
相关论文
共 50 条
  • [31] Response of Complex Undefined Hypereosinophilic Syndrome to Treatment with Imatinib
    Yilmaz, Insu
    Kaynar, Leylagul
    Tutar, Nuri
    Pala, Cigdem
    Canoz, Ozlem
    Yildirim, Afra
    Buyukoglan, Hakan
    Gulmez, Inci
    TURKISH THORACIC JOURNAL, 2016, 17 (03) : 118 - 121
  • [32] Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors
    Liu, Wei Zhen
    Du, Yu Qiang
    Shen, Qian
    Tao, Kai Xiong
    Zhang, Peng
    JOURNAL OF DIGESTIVE DISEASES, 2023,
  • [33] A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update
    Blay, J. Y.
    Casali, P. G.
    Reichardt, P.
    von Mehren, M.
    Debiec-Rychter, M.
    Bailey, S.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia
    Curi, Dany A.
    Beauchamp, Elspeth M.
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1581 - 1582
  • [35] Identification of nilotinib-altered microRNA expression patterns in imatinib-resistant chronic myeloid leukemia cells
    You, Ren-In
    Ho, Ching-Liang
    Hung, Hsiu-Man
    Chao, Tsu-Yi
    BIOMARKERS AND GENOMIC MEDICINE, 2013, 5 (03) : 71 - 73
  • [36] Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice
    DeAngelo, Daniel J.
    Attar, Eyal C.
    LEUKEMIA & LYMPHOMA, 2010, 51 (03) : 363 - 375
  • [37] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [38] Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors
    Serrano, Cesar
    George, Suzanne
    Valverde, Claudia
    Olivares, David
    Garcia-Valverde, Alfonso
    Suarez, Cristina
    Morales-Barrera, Rafael
    Carles, Joan
    TARGETED ONCOLOGY, 2017, 12 (03) : 277 - 288
  • [39] Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
    Giles, Francis J.
    Yin, Ophelia
    Chia, Yen Lin
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 390 - 390
  • [40] When Evaluating Parameter Uncertainty Is Not Enough: The Case of Dasatinib and Nilotinib for Imatinib-Resistant Chronic Myeloid Leukemia
    Reed, Shelby D.
    VALUE IN HEALTH, 2011, 14 (08) : 1055 - 1056
12345